nature research

Corresponding author(s):	Kuan-lin Huang
Last updated by author(s):	Apr 26, 2021

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

C.			
S t	at	ist	ICS

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
\boxtimes	A stateme	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statist	cical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.			
	A description of all covariates tested				
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\boxtimes	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Policy information about <u>availability of computer code</u>					
		Data were derived from clinical records from Mount Sinai facilities using the Epic electronic health record (Epic Systems, Verona, WI). Data were directly extracted from Epic's Clarity and Caboodle servers.			

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

All statistical analyses and data visualizations were carried out using R 4.0.0 (The R foundation, Vienna, Austria). For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Data underlying Figures 1 and 2 are available in Supplementary Data 1 and 2. Other de-identified data is available in accordance with Mount Sinai policy. Requests will be assessed by the Icahn School of Medicine Institutional Data Access Committee (contact via Joy.Dicker@mssm.edu).

Field-specific reporting					
Please select the or	ne below	that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
\(\sum_{\text{life sciences}}\)		Behavioural & social sciences			
For a reference copy of t	he docume	nt with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces	study design			
All studies must dis	close on	these points even when the disclosure is negative.			
Sample size	The sam	ple size was 4,930 after selecting for our patient cohort of interest.			
Data exclusions		out of all COVID-related encounters in the health system up to August 5,2020, we excluded those involving patients <18 years old, those not dmitted to the hospital, and those without a positive COVID test within 2 days of admission.			
Replication	We inclu	/e included a second cohort of patients admitted from August 5, 2020 to January 13, 2021 as a validation cohort.			
Randomization	N/A	N/A			
Blinding	N/A				
Reporting for specific materials, systems and methods We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Materials & exp					
n/a Involved in the study		n/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic	cell lines	Flow cytometry			
Palaeontolo					
Animals and other organisms					
Dual use research of concern					
Clinical data					
Policy information a		nical studies with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.			
Clinical trial regist	Clinical trial registration N/A				
Study protocol		N/A			

Data were derived from clinical records from Mount Sinai facilities using the Epic electronic health record (Epic Systems, Verona, WI).

The primary outcome was death from any cause during admission.

Data collection

Outcomes